BACKGROUND: Random effects models were used to explore how the shape of CD4 cell count responses after commencing combination antiretroviral therapy (cART) develop over time and, in particular, the role of baseline and follow-up covariates. METHODS: Patients in Asia Pacific HIV Observational Database who first commenced cART after January 1, 1997, and who had a baseline CD4 cell count and viral load measure and at least 1 follow-up measure between 6 and 24 months, were included. CD4 cell counts were determined at every 6-month period after the commencement of cART for up to 6 years. RESULTS: A total of 1638 patients fulfilled the inclusion criteria with a median follow-up time of 58 months. Lower post-cART mean CD4 cell counts were found to be associated with increasing age (P < 0.001), pre-cART hepatitis C coinfection (P = 0.038), prior AIDS (P = 0.019), baseline viral load < or equal to 100,000 copies per milliliter (P < 0.001), and the Asia Pacific region compared with Australia (P = 0.005). A highly significant 3-way interaction between the effects of time, baseline CD4 cell count, and post-cART viral burden (P < 0.0001) was demonstrated. Higher long-term mean CD4 cell counts were associated with lower baseline CD4 cell count and consistently undetectable viral loads. Among patients with consistently detectable viral load, CD4 cell counts seemed to converge for all baseline CD4 levels. CONCLUSIONS: Our analysis suggest that the long-term shape of post-cART CD4 cell count changes depends only on a 3-way interaction between baseline CD4 cell count, viral load response, and time.
BACKGROUND: Random effects models were used to explore how the shape of CD4 cell count responses after commencing combination antiretroviral therapy (cART) develop over time and, in particular, the role of baseline and follow-up covariates. METHODS:Patients in Asia Pacific HIV Observational Database who first commenced cART after January 1, 1997, and who had a baseline CD4 cell count and viral load measure and at least 1 follow-up measure between 6 and 24 months, were included. CD4 cell counts were determined at every 6-month period after the commencement of cART for up to 6 years. RESULTS: A total of 1638 patients fulfilled the inclusion criteria with a median follow-up time of 58 months. Lower post-cART mean CD4 cell counts were found to be associated with increasing age (P < 0.001), pre-cART hepatitis C coinfection (P = 0.038), prior AIDS (P = 0.019), baseline viral load < or equal to 100,000 copies per milliliter (P < 0.001), and the Asia Pacific region compared with Australia (P = 0.005). A highly significant 3-way interaction between the effects of time, baseline CD4 cell count, and post-cART viral burden (P < 0.0001) was demonstrated. Higher long-term mean CD4 cell counts were associated with lower baseline CD4 cell count and consistently undetectable viral loads. Among patients with consistently detectable viral load, CD4 cell counts seemed to converge for all baseline CD4 levels. CONCLUSIONS: Our analysis suggest that the long-term shape of post-cART CD4 cell count changes depends only on a 3-way interaction between baseline CD4 cell count, viral load response, and time.
Authors: P M Tarwater; J B Margolick; J Jin; J P Phair; R Detels; C Rinaldo; J Giorgi; A Muñoz Journal: J Acquir Immune Defic Syndr Date: 2001-06-01 Impact factor: 3.731
Authors: T E Yamashita; J P Phair; A Muñoz; J B Margolick; R Detels; S J O'Brien; J W Mellors; S M Wolinsky; L P Jacobson Journal: AIDS Date: 2001-04-13 Impact factor: 4.177
Authors: A N Phillips; S Staszewski; R Weber; O Kirk; P Francioli; V Miller; P Vernazza; J D Lundgren; B Ledergerber Journal: JAMA Date: 2001-11-28 Impact factor: 56.272
Authors: A Mocroft; S Vella; T L Benfield; A Chiesi; V Miller; P Gargalianos; A d'Arminio Monforte; I Yust; J N Bruun; A N Phillips; J D Lundgren Journal: Lancet Date: 1998-11-28 Impact factor: 79.321
Authors: Peter W Hunt; Steven G Deeks; Benigno Rodriguez; Hernan Valdez; Starley B Shade; Donald I Abrams; Mari M Kitahata; Melissa Krone; Torsten B Neilands; Richard J Brand; Michael M Lederman; Jeffrey N Martin Journal: AIDS Date: 2003-09-05 Impact factor: 4.177
Authors: Preeyaporn Srasuebkul; Alexandra Calmy; Jialun Zhou; Nagalingeswaran Kumarasamy; Matthew Law; Poh Lian Lim Journal: AIDS Res Ther Date: 2007-09-17 Impact factor: 2.250
Authors: Mariana Leão de Lima-Stein; Wagner Tadeu Alkmim; Maria Clara de Souza Bizinoto; Luis Fernandez Lopez; Marcelo Nascimento Burattini; Juliana Terzi Maricato; Leila Giron; Maria Cecília Araripe Sucupira; Ricardo Sobhie Diaz; Luiz Mario Janini Journal: AIDS Res Hum Retroviruses Date: 2014-08-25 Impact factor: 2.205
Authors: N Han; S T Wright; C C O'Connor; J Hoy; S Ponnampalavanar; M Grotowski; H X Zhao; A Kamarulzaman Journal: HIV Med Date: 2014-11-18 Impact factor: 3.180
Authors: Stephen T Wright; Andrew Carr; Ian Woolley; Michelle Giles; Jennifer Hoy; David A Cooper; Matthew G Law Journal: J Acquir Immune Defic Syndr Date: 2011-09-01 Impact factor: 3.731
Authors: Kathy Petoumenos; Jun Yong Choi; Jennifer Hoy; Sasisopin Kiertiburanakul; Oon Tek Ng; Mark Boyd; Reena Rajasuriar; Matthew Law Journal: Antivir Ther Date: 2017
Authors: Amit C Achhra; Jialun Zhou; Jun Yong Choi; Jennifer Hoy; Fujie Zhang; David J Templeton; Tuti Merati; Ian Woolley; Kathy Petoumenos; Janaki Amin Journal: J Int Assoc Physicians AIDS Care (Chic) Date: 2011-04-20
Authors: S T Wright; K Petoumenos; M Boyd; A Carr; S Downing; C C O'Connor; M Grotowski; M G Law Journal: HIV Med Date: 2012-10-04 Impact factor: 3.180
Authors: Sabine M Hermans; Agnes N Kiragga; Petra Schaefer; Andrew Kambugu; Andy I M Hoepelman; Yukari C Manabe Journal: PLoS One Date: 2010-05-07 Impact factor: 3.240